Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Acquisitions & Divestments (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Change in Acquisitions & Divestments data on record, last reported at $144.8 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 34.85% year-over-year to $144.8 million; the TTM value through Dec 2025 reached $486.0 million, up 44.1%, while the annual FY2025 figure was $486.0 million, 44.1% up from the prior year.
  • Change in Acquisitions & Divestments reached $144.8 million in Q4 2025 per SNDX's latest filing, up from $103.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $154.9 million in Q2 2023 and bottomed at $37.5 million in Q1 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $92.9 million, with a median of $94.9 million recorded in 2021.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 363.73% in 2021, then tumbled 60.14% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $45.4 million in 2021, then soared by 149.45% to $113.2 million in 2022, then fell by 0.22% to $113.0 million in 2023, then decreased by 5.01% to $107.3 million in 2024, then surged by 34.85% to $144.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $144.8 million in Q4 2025, $103.0 million in Q3 2025, and $133.6 million in Q2 2025.